| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
185,611,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
6,246,627 |
Avg
Vol: |
2,858,046 |
| 52
Week Range: |
$23.99 - $23.99 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-25 |
2023-11-24 |
2023-05-26 |
2022-05-26 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Whelan Jr. Robert M. |
Director |
• • – |
2012-12-26 |
4 |
GA |
$0.00 |
$0 |
I/I |
35,000 |
35,000 |
|
- |
|
| Whelan Jr. Robert M. |
Director |
• • – |
2012-12-26 |
4 |
GD |
$0.00 |
$0 |
D/D |
35,000 |
18,359 |
|
- |
|
| Lavidas Athanese |
Director |
• • – |
2012-12-21 |
4 |
S |
$20.31 |
$213,209 |
D/D |
(10,500) |
80,131 |
|
- |
|
| Clackson Timothy P |
President, R&D, CSO |
• • – |
2012-12-20 |
4 |
OE |
$5.23 |
$141,210 |
D/D |
27,000 |
282,940 |
|
- |
|
| Keane Raymond T |
SVP General Counsel & CCO |
• • – |
2012-12-18 |
4 |
D |
$20.18 |
$65,302 |
D/D |
(3,236) |
36,014 |
|
- |
|
| Keane Raymond T |
SVP General Counsel & CCO |
• • – |
2012-12-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,750 |
39,250 |
|
- |
|
| Fitzgerald Edward M |
Executive VP, CFO |
• • – |
2012-12-18 |
4 |
D |
$20.18 |
$164,306 |
D/D |
(8,142) |
191,357 |
|
- |
|
| Fitzgerald Edward M |
Executive VP, CFO |
• • – |
2012-12-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
19,500 |
199,499 |
|
- |
|
| Dodion Pierre F |
SVP, Corp. Dev. & Operations |
• • – |
2012-12-18 |
4 |
D |
$20.18 |
$75,836 |
D/D |
(3,758) |
38,282 |
|
- |
|
| Dodion Pierre F |
SVP, Corp. Dev. & Operations |
• • – |
2012-12-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,000 |
42,040 |
|
- |
|
| Berstein David L |
Senior VP, Chief IP Officer |
• • – |
2012-12-18 |
4 |
D |
$20.18 |
$75,836 |
D/D |
(3,758) |
187,098 |
|
- |
|
| Berstein David L |
Senior VP, Chief IP Officer |
• • – |
2012-12-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,000 |
190,856 |
|
- |
|
| Bollag Daniel M |
Sr. VP, Reg. Affairs & Quality |
• • – |
2012-12-18 |
4 |
D |
$20.18 |
$75,836 |
D/D |
(3,758) |
91,271 |
|
- |
|
| Bollag Daniel M |
Sr. VP, Reg. Affairs & Quality |
• • – |
2012-12-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,000 |
95,029 |
|
- |
|
| Clackson Timothy P |
President, R&D, CSO |
• • – |
2012-12-18 |
4 |
D |
$20.18 |
$164,306 |
D/D |
(8,142) |
255,940 |
|
- |
|
| Clackson Timothy P |
President, R&D, CSO |
• • – |
2012-12-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
19,500 |
264,082 |
|
- |
|
| Cantor Maria E |
SVP, Corporate Affairs |
• • – |
2012-12-18 |
4 |
D |
$20.18 |
$107,438 |
D/D |
(5,324) |
40,673 |
|
- |
|
| Cantor Maria E |
SVP, Corporate Affairs |
• • – |
2012-12-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
12,750 |
45,997 |
|
- |
|
| Haluska Frank |
SVP, Clinical R&D, CMO |
• • – |
2012-12-18 |
4 |
D |
$20.18 |
$107,438 |
D/D |
(5,324) |
57,207 |
|
- |
|
| Haluska Frank |
SVP, Clinical R&D, CMO |
• • – |
2012-12-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
12,750 |
62,531 |
|
- |
|
| Berger Harvey J MD |
Chairman & CEO |
• • – |
2012-12-18 |
4 |
D |
$20.18 |
$526,577 |
D/D |
(26,094) |
2,226,089 |
|
- |
|
| Berger Harvey J MD |
Chairman & CEO |
• • – |
2012-12-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
62,500 |
2,252,183 |
|
- |
|
| Lamarche Jay R |
Director |
• • – |
2012-10-01 |
4 |
AS |
$24.99 |
$249,932 |
D/D |
(10,000) |
400,705 |
|
- |
|
| Fitzgerald Edward M |
Executive VP, CFO |
• • – |
2012-10-01 |
4 |
AS |
$24.17 |
$604,188 |
D/D |
(25,000) |
179,767 |
|
- |
|
| Bollag Daniel M |
Sr. VP, Reg. Affairs & Quality |
• • – |
2012-10-01 |
4 |
AS |
$25.00 |
$187,500 |
D/D |
(7,500) |
85,519 |
|
- |
|
703 Records found
|
|
Page 17 of 29 |
|
|
